SEARCH
Current Location:
>
> This Story


Log in or Register to rate this News Story
Forward Printable StoryPrint Comment

Never Miss a Story

Sign up for email alerts

 

More Industry Headlines

Toshiba to sell non-imaging health care business in addition to Medical Systems division Stock in the company has hit 35-year low

MR illuminates link between multiple sclerosis, inferior ability to taste MS brain lesions inversely correlate with taste capability: report

Pacemaker and ICD battery life needs to be extended to last 25 years Replacing batteries can lead to life-threatening infections

New telehealth legislation getting support from all angles CONNECT for Health Act gaining bipartisan, industry traction

Calling for a more personalized approach to preventing breast and ovarian cancers Psychological and medical risks need to be considered

Exposing the secrets of voodoo dolls through X-ray Virtual autopsy yields forensic insights in Haitian voodoo crimes

Portable seizure device yields unexpected mood benefits to PTSD patients Reduced sleeplessness, depression and nightmares by 30 percent

MR-compatible cardiac device implants add significant value to patient care A first-of-its-kind study finds value providers may be drawn to

Proton therapy is best for the most common pediatric brain tumor: study Medulloblastoma side effects diminished relative to conventional therapy

PET/CT beats CT and bone scans for detecting metastatic prostate cancer: study PET imaging of prostate has 'exploded' over last two years

Will CMS revise its coverage policy for new PET agents?

by Loren Bonner , DOTmed News Online Editor
The Centers for Medicare and Medicaid Services is in the process of reconsidering its coverage determination for PET radiopharmaceuticals outside of the four it currently reimburses. Stakeholders feel it's important to simplify the process for assessing and approving new PET imaging agents for reimbursement, particularly in light of several new ones coming down the pipeline. Many of these new agents will evaluate myocardial perfusion, as well as the pathophysiology of Alzheimer's disease and Parkinson's disease.

"To go indication by indication on all these new agents we expect to hopefully be approved over the next few years will be a bit cumbersome," said Frederic Fahey, president of the Society of Nuclear Medicine and Molecular Imaging (now SNMMI, formerly SNM).

Story Continues Below Advertisement

VIP Medical, Inc. - A Reputation For Quality!!! Visit www.vipmedinc.com

Our primary focus is International wholesale distribution of Pre-owned Medical Equipment. We specialize in Respiratory Equipment, primarily adult and infant ventilators. All major OEMs supported. Call 703-589-0369. DOTmed Certified



SNMMI, in conjunction with the Medical Imaging and Technology Alliance, American College of Radiology, Council on Radionuclides and Radiopharmaceuticals, and World Molecular Imaging Society, are backing this request to remove a second layer of approval outside the FDA's. Discussions have been ongoing for the past year with CMS, and a formal letter was sent to the agency at the end of March.

CMS has a national coverage determination in place denying reimbursement for PET agents outside of its approved list.

"Once you've gone through the rather rigorous FDA process including showing efficacy, you've done a pretty decent job of showing the indications that are being recommended for that agent," said Fahey.

The letter that was submitted to CMS from the five agencies goes on to say that recent advances in imaging and CMS' past experience with PET coverage no longer support a clinical rationale for a national noncoverage policy for new PET agents that have undergone FDA review and approval.

"In my mind, the old way may have been reasonable for FDG. FDG is a pretty non-specific agent. It goes a lot of different places and is used for many different things. But I think as we move forward into molecular imaging, more targeted and hopefully more specific imaging for a particular patient, the indications are probably not going to be as broad and wide," said Fahey.

CMS is accepting public comments until Aug. 10 to determine whether to cover remaining uses of PET.

Related:


Interested in Medical Industry News? Subscribe to DOTmed's weekly news email and always be informed. Click here, it takes just 30 seconds.

You Must Be Logged In To Post A Comment

Advertise
Increase Your
Brand Awareness
Auctions + Private Sales
Get The
Best Price
Buy Equipment/Parts
Find The
Lowest Price
Daily News
Read The
Latest News
Directory
Browse All
DOTmed Users
Ethics on DOTmed
View Our
Ethics Program
Gold Parts Vendor Program
Receive PH
Requests
Gold Service Dealer Program
Receive RFP/PS
Requests
Healthcare Providers
See all
HCP Tools
Jobs/Training
Find/Fill
A Job
Parts Hunter +EasyPay
Get Parts
Quotes
Recently Certified
View Recently
Certified Users
Recently Rated
View Recently
Certified Users
Rental Central
Rent Equipment
For Less
Sell Equipment/Parts
Get The
Most Money
Service Technicians Forum
Find Help
And Advice
Simple RFP
Get Equipment
Quotes
Virtual Trade Show
Find Service
For Equipment
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2016 DOTmed.com, Inc.
ALL RIGHTS RESERVED